Upper Gastrointestinal and Endocrine Tumor Group Archives

First targeted radioligand therapy to demonstrate significant and clinically meaningful impact in first-line advanced gastroenteropancreatic neuroendocrine tumors

Results of the multi-center, randomized, comparator-controlled phase III NETTER-2 trial show that first-line treatment with radioligand therapy 177LU-DOTATATE in combination…